TruScreen Group (TRU) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
1 Sep, 2026Opening remarks and agenda
Meeting opened with a welcome to shareholders, both in-person and online, and introduction of the board and key executives.
Apologies were extended for the absence of a director due to family reasons.
Voting procedures were outlined, with all resolutions to be voted on by poll at the end of the meeting.
The agenda included CEO presentation, formal resolutions, general business session, and a technology overview covering market landscape, sales strategy, and financial performance.
Board and executive committee updates
Board refresh included the appointment of Christine Pears and the retirement of Chris Horn after 13 years.
Rhys O'Connell was introduced as a new director, bringing commercial and market expertise.
The board composition now includes both New Zealand and Australian directors, with adjustments in director remuneration to reflect currency differences.
Tony Ho (Non-Executive Chairman) and Marty Dillon (CEO) provided contact details and led the meeting.
Financial performance review
FY26 annual sales reached NZ$2.4m, a 42% year-on-year increase.
Total revenue for FY26 was NZ$2.8m, up 33% year-on-year, including R&D tax offsets.
Market capitalization as of August 2026 was NZ$15.7m, with 1,047,718,877 shares on issue.
Net assets increased 160% year-on-year due to fundraising and inventory investment.
NZ$5m capital was raised in June 2026 through oversubscribed placements and rights offers.
Latest events from TruScreen Group
- Shareholders approved key capital raising measures and director incentives, with voting results pending.TRU
EGM 2026 - FY2025 sales fell on rollout delays, but FY2026 is set for strong growth with new markets and alliances.TRU
H2 2025 - Revenue down 17% to NZ$860k; capital raised and public programs set to drive 2H growth.TRU
H1 2026 - Sales up 42% YOY, gross margin 31.5%, and $4m raised to fund global expansion.TRU
H2 2026 - AI-driven cervical cancer screening device posts rapid sales growth and global expansion.TRU
Investor presentation - AI-driven cervical cancer screening sales up 27% YOY, led by China and LMIC expansion.TRU
Investor presentation - FY26 sales projected to surpass NZ$2.8m as public programs and new markets accelerate growth.TRU
Investor presentation - FY26 growth is driven by public program expansion, new markets, and product diversification.TRU
AGM 2025 - Sales up 5% year-over-year, with narrowed operating loss and expanding global adoption.TRU
H1 2025